Stockscreener 앱 받기
0.401
5.50%
0.0209
시간 외 거래:
.42
0.019
+4.74%
전일 마감가:
$0.3801
열려 있는:
$0.380001
하루 거래량:
978.76K
Relative Volume:
0.17
시가총액:
$8.73M
수익:
$200.00K
순이익/손실:
$-10.95M
주가수익비율:
-0.2032
EPS:
-1.9738
순현금흐름:
$-10.78M
1주 성능:
+0.25%
1개월 성능:
+10.13%
6개월 성능:
-63.55%
1년 성능:
-88.07%
1일 변동 폭
$0.38
$0.4219
1주일 범위
$0.38
$0.4219
52주 변동 폭
$0.28
$3.44
Soligenix Inc Stock (SNGX) Company Profile
명칭
Soligenix Inc
전화
609-538-8200
주소
29 EMMONS DRIVE, PRINCETON
Compare SNGX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNGX
Soligenix Inc
|
0.401 | 8.27M | 200.00K | -10.95M | -10.78M | -1.9738 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Soligenix Inc Stock (SNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-07-28 | 다운그레이드 | Dawson James | Buy → Neutral |
| 2018-01-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-08-14 | 재확인 | Maxim Group | Buy |
| 2017-07-17 | 개시 | H.C. Wainwright | Buy |
Soligenix Inc 주식(SNGX)의 최신 뉴스
Soligenix (SNGX) Earnings Reading: The EPS Result Is Above Expectation in the Latest Session; Share Move - dars.gov.et
Soligenix (SNGX) Financial Results: The EPS Result Is Above Expectation in the Latest Reading; Latest Reaction: Shares Finish 3.79% Lower in the Available RecordRevenue Beat Analysis - vinanet.vn
SNGX Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Marginal BeatAnalyst Coverage Count - vinanet.vn
Soligenix Stock Price Forecast. Should You Buy SNGX? - StockInvest.us
SNGX Q1 2026 Earnings: Narrower Loss Offers Slight Beat, Yet No Revenue and Stock DipEarnings Trend Analysis - Vinanet
SNGX: Applying for Vaccine Development Funding for Ebola Vaccine - Smartkarma
Soligenix to Present at BIO Investment & Growth Summit (PR Newswire) - Aktiellt
SNGX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Share ReactionMid-Term Outlook - vinanet.vn
Soligenix culls topical lymphoma asset after Phase III miss - Yahoo Finance
Soligenix (SNGX) Receives a Buy from Alliance Global Partners - The Globe and Mail
A. G. P. Maintains Soligenix(SNGX.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Soligenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Soligenix Q2 net loss narrows as R&D expenses fall - TradingView
Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results - Barchart.com
SNGX Q1 2026 Earnings: Narrower Loss Provides Modest Upside SurpriseEarnings Beat Streak - vinanet.vn
Soligenix Inc (SNGX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Soligenix Inc. R (DOA0.MU) stock price, news, quote and history - Yahoo Finance UK
SOLIGENIX, INC. SEC Filing (Aug 3, 2026) - Stock Titan
SNGX Q1 2026 Earnings: Narrow Loss Beat Fails to Move SharesROE Trend Analysis - vinanet.vn
SNGX Q1 2026 Earnings: Narrower-Than-Expected Loss in a Revenue-Empty QuarterRevenue Growth Report - Vinanet
Soligenix Inc (SNGX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Soligenix Inc. (SNGX) Q1 2026 Earnings: Narrower Loss Per Share Signals Cost Management, but No Revenue ReportedMid-Term Outlook - dars.gov.et
Soligenix Inc (SNGX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Soligenix Inc (SNGX) Cash Flow - TradingKey
Soligenix Inc (SNGX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SNGX Stock Price, Quote & Chart - ChartMill
Soligenix Inc (SNGX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Soligenix Inc (SNGX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
SNGX|Soligenix Inc|Price:0.374|Chg%:-0.001 - tradingkey.com
Soligenix Inc (SNGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Soligenix Inc (SNGX) Institutional Confidence - TradingKey
Soligenix Inc (SNGX) Income Statement - TradingKey
SNGX|Soligenix Inc|Price:0.400|Chg%:+0.019 - TradingKey
Soligenix, Inc. Revenue Breakdown – NASDAQ:SNGX - TradingView
SNGX Q1 2026 Earnings: EPS Beat Driven by Cost Management Amid No RevenueProfit Margin Analysis - vinanet.vn
SNGX|Soligenix Inc|Price:0.371|Chg%:-0.002 - TradingKey
Soligenix (SNGX) seeks reverse stock split and higher authorized shares - Stock Titan
Soligenix (SNGX) Q1 2026 Earnings: Narrower-than-expected net loss per share amid steady pipeline advancement - dars.gov.et
SNGX News | SOLIGENIX INC (NASDAQ:SNGX) - ChartMill
Soligenix (SNGX) seeks reverse stock split, higher share authorization to protect Nasdaq listing - Stock Titan
SNGX Q1 2026 Earnings: Narrower-Than-Expected Loss as Biotech Advances Pipeline with No RevenueRetail Earnings Report - vinanet.vn
Soligenix Inc. (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Continued Pipeline ProgressEstimate Uncertainty - dars.gov.et
Soligenix (SNGX) Edges Higher Amid Key Resistance TestMomentum Breakout Ideas - dars.gov.et
Soligenix (SNGX) Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline Development ContinuesAnnual Earnings Summary - dars.gov.et
Soligenix Q1 2026 Earnings: Narrower-than-Expected Loss Reflects Cost ManagementAnalyst Drop Coverage - dars.gov.et
Soligenix (SNGX) Q1 2026 Earnings: Small EPS Beat Amid Continued Pipeline ProgressEstimate Dispersion - dars.gov.et
Soligenix, Inc. Financial Disclosures & SEC Filings - TradingView
Soligenix Expands At-the-Market Equity Offering Capacity - The Globe and Mail
SNGX Stock Slumps To Record Low After Lymphoma Trial Fails – All Eyes Now On Behçet’s Disease Treatment - Stocktwits
Form 424B5 Soligenix Inc For: 26 June - Investing.com UK
Form 424B5 Soligenix Inc For: 26 June By Investing.com - Investing.com Nigeria
Soligenix Inc (SNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.21%
1.07%
자본화:
|
볼륨(24시간):